Artelo Biosciences Reports Increased Net Loss and Deteriorating Financial Position for First Half of 2025

Artelo Biosciences, Inc. reported a net loss of $5.6 million for the six months ended June 30, 2025, compared to a net loss of $4.9 million for the same period in 2024. The company's total operating expenses increased to $5.5 million from $5.1 million year-over-year, primarily driven by higher professional fees related to capital-raising efforts and increased research and development expenditures. The company did not generate any revenue during this period, consistent with its historical performance since inception.

As of June 30, 2025, Artelo's cash and cash equivalents stood at $2.1 million, a decrease from $2.3 million at the end of 2024. The company's current liabilities surged to $5.7 million from $1.8 million, reflecting a cash preservation strategy that involved deferring payments on certain payables. Consequently, the working capital position deteriorated to a deficit of $3.5 million, compared to a positive working capital of $785,000 at the end of the previous fiscal year.

In terms of strategic developments, Artelo completed a private placement on June 26, 2025, raising gross proceeds of $1.4 million through the issuance of common stock and warrants. Additionally, the company entered into an At-The-Market Offering Agreement in July 2025, allowing it to sell up to $6.5 million in common stock over time. A significant organizational change occurred with a one-for-six reverse stock split effective June 13, 2025, aimed at improving the company's stock price and marketability.

Operationally, Artelo is advancing its clinical programs, including the ART27.13 candidate for cancer-related anorexia, which is currently in a Phase 2a trial. The company has opened 15 clinical sites across five countries for this study. Despite these advancements, the company continues to face challenges in securing sufficient funding to support ongoing operations and development activities. The management has indicated that additional capital will be necessary to continue operations, raising substantial doubt about the company's ability to continue as a going concern within the next year.

Looking ahead, Artelo is pursuing various financing strategies to bolster its capital resources, including potential equity or debt offerings. The company has also adopted a Digital Asset Treasury strategy, committing to purchase the digital currency Solana (SOL) as part of its treasury management. However, the company acknowledges the inherent risks associated with its financial condition and the volatile nature of digital assets, which could impact its future operations and financial performance.